UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - CHINA BIOLOGIC PRODS HLDGS I ownership

Quarter-by-quarter ownership
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ownership history of CHINA BIOLOGIC PRODS HLDGS I
ValueSharesWeighting
Q1 2021$566,947,000
-23.5%
4,788
-23.7%
0.00%
Q4 2020$741,495,000
+6.3%
6,2780.0%0.00%
Q3 2020$697,737,000
+91.3%
6,278
+75.9%
0.00%
Q2 2020$364,783,000
-5.3%
3,5700.0%0.00%
Q1 2020$385,310,000
-7.3%
3,5700.0%0.00%
Q4 2019$415,477,000
-58.9%
3,570
-59.6%
0.00%
-100.0%
Q3 2019$1,012,029,000
+169.6%
8,841
+124.4%
0.00%
Q2 2019$375,387,000
-87.6%
3,939
-88.2%
0.00%
-100.0%
Q1 2019$3,035,888,000
-81.0%
33,270
-84.2%
0.00%
-85.7%
Q4 2018$15,996,059,000
-2.7%
210,724
+2.6%
0.01%
+16.7%
Q3 2018$16,433,920,000205,4240.01%
Other shareholders
CHINA BIOLOGIC PRODS HLDGS I shareholders Q2 2024
NameSharesValueWeighting ↓
Maso Capital Partners Ltd 143,300$11,464,00011.16%
Hillhouse Capital Management 2,751,200$220,096,0005.88%
York Capital Management Global Advisors, LLC 1,167,643$93,411,0002.95%
Kite Lake Capital Management (UK) LLP 152,836$12,227,0002.53%
RUDMAN ERROL M 80,000$6,400,0002.39%
Dalton Investments, Inc. 54,551$4,364,0002.04%
Greenwoods Asset Management Ltd 245,000$19,600,0001.91%
Point72 Hong Kong Ltd 47,296$3,784,0001.29%
Temasek Holdings (Private) Ltd 990,000$79,200,0000.46%
Kassirer Asset Management Corp 6,000$480,0000.32%
View complete list of CHINA BIOLOGIC PRODS HLDGS I shareholders